St. Louis biotech firm reaches key milestone with Covid-19 treatment
The drug has been developed by St. Louis firm Confluence Discovery Technologies, a subsidiary of Pennsylvania-based clinical-stage biopharmaceutical company Aclaris Therapeutics.
The drug has been developed by St. Louis firm Confluence Discovery Technologies, a subsidiary of Pennsylvania-based clinical-stage biopharmaceutical company Aclaris Therapeutics.